Inter-dialytic variations in blood volume and total body water in uraemic patients treated by dialysis

Why is Intradialytic Hypotension the Commonest Complication of Outpatient Dialysis Treatments?

Intradialytic hypotension (IDH) is the most frequent complication of hemodialysis (HD) treatments with a frequency of 10% to 12% for patients with chronic kidney disease attending for outpatient treatments and is associated with both temporary ischemic stress to vital organs, including the heart and brain, and increased patient mortality. Although there have been many different definitions of IDH over the years, an absolute nadir systolic blood pressure (SBP) has the strongest association with patient outcomes. The unifying pathophysiology is one of reduced effective blood volume, resulting in lower plasma tonicity, and if this cannot be adequately compensated for by activation of neurohumeral systems, then arteriolar tone and blood pressure fall. The risk factors for developing IDH are numerous, ranging from patient-related factors, including age and comorbidity with reduced cardiac reserve, to patient compliance with dietary and lifestyle advice, to reactions with the extracorporeal circuit and medications, choice of dialysate composition and temperature, setting of postdialysis target weight, ultrafiltration rate, and profiling. Advances in dialysis machine technology by providing real time estimates of the effective circulating volume and adjusting dialysate composition to maintain vascular tonicity are being developed, but currently require more sophisticated biofeedback loops to be clinically effective in preventing IDH. While awaiting advances in artificial intelligence, the clinician continues to rely on patient education to limit interdialytic weight gains, frequent assessment of the postdialysis target weight, adjusting dialysate composition and temperature, introducing convective therapies to increase thermal losses, and altering dialysis session duration and frequency to reduce ultrafiltration rate requirements.

Water - A life-giving toxin - A nephrological oxymoron. Health consequences of water and sodium balance disorders. A review article

BACKGROUND

This article aims to reveal misconceptions about methods of assessment of hydration status and impact of the water disorders on the progression of kidney disease or renal dysfunction.

MATERIALS AND METHODS

The PubMed database was searched for reviews, meta-analyses and original articles on hydration, volume depletion, fluid overload and diagnostic methods of hydration status, which were published in English.

RESULTS

Based on the results of available literature the relationship between the amount of fluid consumed, and the rate of progression of chronic kidney disease, autosomal dominant polycystic kidney disease, and kidney stones disease was discussed. Selected aspects of the assessment of the hydration level in clinical practice based on physical examination, laboratory tests, and imaging are presented. The subject of in-hospital fluid therapy is discussed. Based on available randomized studies, an attempt was made to assess, which fluids should be selected for intravenous treatment.

CONCLUSIONS

There is some evidence for the beneficial effect of increased water intake in preventing recurrent cystitis and kidney stones, but there are still no convincing data for chronic kidney disease and autosomal dominant polycystic kidney disease. Further studies are needed to clarify the aforementioned issues and establish a reliable way to assess the volemia and perform suitable fluid therapy.

Estimated plasma volume status (ePVS) is a predictor for acute myocardial infarction in-hospital mortality: analysis based on MIMIC-III database

BACKGROUND

Estimated plasma volume status (ePVS) has been reported that associated with poor prognosis in heart failure patients. However, no researchinvestigated the association of ePVS and prognosis in patients with acute myocardial infarction (AMI). Therefore, we aimed to determine the association between ePVS and in-hospital mortality in AMI patients.

METHODS AND RESULTS

We extracted AMI patients data from MIMIC-III database. A generalized additive model and logistic regression model were used to demonstrate the association between ePVS levels and in-hospital mortality in AMI patients. Kaplan-Meier survival analysis was used to pooled the in-hospital mortality between the various group. ROC curve analysis were used to assessed the discrimination of ePVS for predicting in-hospital mortality. 1534 eligible subjects (1004 males and 530 females) with an average age of 67.36 ± 0.36 years old were included in our study finally. 136 patients (73 males and 63 females) died in hospital, with the prevalence of in-hospital mortality was 8.9%. The result of the Kaplan-Meier analysis showed that the high-ePVS group (ePVS ≥ 5.28 mL/g) had significant lower survival possibility in-hospital admission compared with the low-ePVS group (ePVS < 5.28 mL/g). In the unadjusted model, high-level of ePVS was associated with higher OR (1.09; 95% CI 1.06-1.12; P < 0.001) compared with low-level of ePVS. After adjusted the vital signs data, laboratory data, and treatment, high-level of ePVS were also associated with increased OR of in-hospital mortality, 1.06 (95% CI 1.03-1.09; P < 0.001), 1.05 (95% CI 1.01-1.08; P = 0.009), 1.04 (95% CI 1.01-1.07; P = 0.023), respectively. The ROC curve indicated that ePVS has acceptable discrimination for predicting in-hospital mortality. The AUC value was found to be 0.667 (95% CI 0.653-0.681).

CONCLUSION

Higher ePVS values, calculated simply from Duarte's formula (based on hemoglobin/hematocrit) was associated with poor prognosis in AMI patients. EPVS is a predictor for predicting in-hospital mortality of AMI, and could help refine risk stratification.

Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study

Background

Short-term hemoglobin (Hb) variability related to volume status is observed in chronic kidney disease (CKD) patients receiving hemodialysis (HD). Given the lack of studies regarding outcomes according to the day of Hb sampling, the existing guidelines do not strongly recommend regarding measurement timing. Pre-dialysis mid-week sampling (Wednesday and Thursday) is preferable to minimize short-term Hb variability, although numerous HD centers perform early-week sampling (Monday and Tuesday). The different measurement days may influence the prescribed dose of erythropoiesis-stimulating agent (ESA) and related patient outcomes. We investigated changes in Hb levels and ESA doses according to the Hb measurement day among HD patients.

Methods

Starting September 2013, the day for pre-dialysis Hb measurement at the Asan Medical Center was changed from early-week days to mid-week days. This single-center retrospective study evaluated medical records of 92 patients who received maintenance HD between September 2012 and August 2014.

Results

There was no significant difference in the mean Hb levels between early-week days and mid-week days (10.71 ± 0.06 g/dL vs. 10.78 ± 0.47 g/dL, p = 0.105). However, the mean doses of darbepoetin-α on early-week days were higher than those on mid-week days (175.4 ± 72.5 μg/month vs. 163.7 ± 83.6 μg/month, p = 0.022). The mean doses of intravenous iron hydroxide sucrose for early-week measurements were also higher than those for mid-week measurements (623.0 ± 489.0 mg/year vs. 447.0 ± 505.2 mg/year, p = 0.001). The mean interdialytic weight gains were 2.81 ± 0.82 kg on early-week days and 1.99 ± 0.61 kg on mid-week days (p < 0.001).

Conclusions

Compared with early-week measurements, mid-week pre-dialysis Hb measurements were significantly associated with lower ESA doses without a change in Hb levels.

Dialysis Prescription and Sudden Death

In the United States, end-stage renal disease patients receiving hemodialysis have an exceedingly high risk of sudden cardiac death (SCD), accounting for 29% of death events, likely relating to their uremic milieu, recurring exposure to fluid and electrolyte fluxes, and underlying cardiovascular pathology. Furthermore, epidemiologic studies have shown that SCD events, as well as mortality and hospitalizations, occur most frequently on the first dialysis day after the long interdialytic gap, suggesting that abrupt fluctuations in the accumulation and removal of electrolytes, fluid, and uremic toxins over the dialysis cycle may be contributory. Some population-based observational studies have suggested that lower dialysate potassium concentrations appear to be associated with a heightened risk of postdialysis cardiac arrest in hemodialysis patients, although the optimal serum-to-dialysate potassium gradient remains unclear. Some observational studies have suggested that low dialysate calcium concentrations and high serum-to-dialysate calcium gradients may predispose patients to SCD. There is ongoing controversy about an association between higher dialysate bicarbonate concentrations and higher risk of cardiac arrest, likely owing to confounding by indication. Some observational studies also have shown that large interdialytic weight gains, fluid retention, and high ultrafiltration rates are linked with higher risk of SCD and mortality. However, there remains considerable controversy regarding the pros and cons of designating a specific upper ultrafiltration limit with extended treatment times as a clinical practice measure, and further studies are needed to define the optimal tools, metrics, targets, and implementation measures for volume control in the hemodialysis population. In this review, we highlight the epidemiology and pathophysiology of how specific aspects of the hemodialysis procedure may relate to the risk of SCD, as well as preventative strategies and future research directions that can address this risk.

Changes in Total Protein Concentration Due to Fluid Removal During and Shortly after Hemodialysis

BACKGROUND

Changes in plasma volume during hemodialysis are complex and have been shown to depend on the rate of fluid removal and the degree of fluid overload. We examined changes in total protein concentration during and shortly after a dialysis treatment in archived data from the HEMO study.

METHODS

During follow-up months 4 and 36 of the HEMO study, additional blood samples were obtained during a typical dialysis session at 30 and 60 min after dialysis. In 315 studies from 282 patients where complete data were available, we calculated the concentration change in total protein and compared it to the modeled change in both total body water and extracellular fluid space as derived from 2-pool urea kinetic modeling.

RESULTS

The mean postdialysis modeled urea volume (V) was 31.1 ± 6.18 L. Mean fluid removal was 2.76 ± 1.27 kg, over a session length of 207 ± 28 min. The ratio of predialysis V to postdialysis V averaged 1.090 ± 0.040. The mean TP ratios (post/pre) at 0, 30, and 60 min postdialysis averaged 1.121 ± 0.070 (SD), 1.091 ± 0.090, and 1.091 ± 0.086. The dialysate to serum sodium gradient, studied in a different group of treatments where this information was available, had no impact on these findings, nor did the length of the interdialytic interval.

CONCLUSIONS

On average, after equilibration, the change in plasma volume due to fluid removal is similar to the modeled change in total body water (urea space), irrespective of dialysate to serum sodium gradient. This supports previous observations that during dialysis with ultrafiltration, plasma volume contracts to a lesser degree than the interstitial volume and that some fluid may be removed from spaces other than the extracellular fluid.

Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal?

Evidence suggests that patients receiving intermittent maintenance hemodialysis treatments experience higher mortality the day after the long 2-day interdialytic gap. A new study confirms higher mortality and reports increased hospitalization immediately after the long interdialytic interval among incident hemodialysis patients in the United Kingdom. Larger fluid accumulation followed by excessive ultrafiltration and abrupt fluctuations in serum potassium concentrations may be among potential factors contributing to the morbidity and mortality of this precarious period.

Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysis

Objectives

Cardiomyopathy is a key factor in accelerated cardiovascular mortality in haemodialysis (HD) patients. We aimed to phenotype cardiac and vascular dysfunction by tagged cardiovascular magnetic resonance (CMR) imaging in patients recently commencing HD.

Methods

Fifty-four HD patients and 29 age and sex-matched controls without kidney disease were studied. Left ventricular (LV) mass, volumes, ejection fraction (EF), concentric remodelling, peak-systolic circumferential strain (PSS), peak diastolic strain rate (PDSR), LV dyssynchrony, aortic distensibility and aortic pulse wave velocity were determined.

Results

Global systolic function was reduced (EF 51 ± 10%, HD versus 59 ± 5%, controls, p < 0.001; PSS 15.9 ± 3.7% versus 19.5 ± 3.3%, p < 0.001). Diastolic function was decreased (PDSR 1.07 ± 0.33s^-1 versus 1.31 ± 0.38s^-1, p = 0.003). LV mass index was increased (63[54,79]g/m² versus 46[42,53]g/m², p < 0.001). Anteroseptal reductions in PSS were apparent. These abnormalities remained prevalent in the subset of HD patients with preserved EF >50% (n = 35) and the subset of HD patients without diabetes (n = 40). LV dyssynchrony was inversely correlated to diastolic function, EF and aortic distensibility. Diastolic function was inversely correlated to LV dyssynchrony, concentric remodelling, age and aortic pulse wave velocity.

Conclusion

Patients new to HD have multiple cardiac and aortic abnormalities as characterised by tagged CMR. Cardio-protective interventions are required from initiation of therapy.

Key Points

• First characterisation of cardiomyopathy by tagged CMR in haemodialysis patients.

• Diastolic function was correlated to LV dyssynchrony, concentric remodelling and aortic PWV.

• Reductions in strain localised to the septal and anterior wall.

• Bioimpedance measures were unrelated to LV strain, suggesting volume-independent pathogenetic mechanisms.

• Multiple abnormalities persisted in the HD patient subset with preserved EF or without diabetes.

Electronic supplementary material

The online version of this article (doi:10.1007/s00330-015-4096-2) contains supplementary material, which is available to authorized users.

Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients

BACKGROUND AND OBJECTIVES

Cardiovascular disease is the most common cause of death in patients on hemodialysis (HD). HD-associated cardiomyopathy is appreciated to be driven by exposure to recurrent and cumulative ischemic insults resulting from hemodynamic instability of conventionally performed intermittent HD treatment itself. Cooled dialysate reduces HD-induced recurrent ischemic injury, but whether this confers long-term protection of the heart in terms of cardiac structure and function is not known.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

Between September 2009 and January 2013, 73 incident HD patients were randomly assigned to a dialysate temperature of 37°C (control) or individualized cooling at 0.5°C below body temperature (intervention) for 12 months. Cardiac structure, function, and aortic distensibility were assessed by cardiac magnetic resonance imaging. Mean between-group difference in delivered dialysate temperature was 1.2°C±0.3°C. Treatment effects were determined by the interaction of treatment group with time in linear mixed models.

RESULTS

There was no between-group difference in the primary outcome of left ventricular ejection fraction (1.5%; 95% confidence interval, -4.3% to 7.3%). However, left ventricular function assessed by peak systolic strain was preserved by the intervention (-3.3%; 95% confidence interval, -6.5% to -0.2%) as was diastolic function (measured as peak diastolic strain rate, 0.18 s(-1); 95% confidence interval, 0.02 to 0.34 s(-1)). Reduction of left ventricular dilation was demonstrated by significant reduction in left ventricular end-diastolic volume (-23.8 ml; 95% confidence interval, -44.7 to -2.9 ml). The intervention was associated with reduced left ventricular mass (-15.6 g; 95% confidence interval, -29.4 to -1.9 g). Aortic distensibility was preserved in the intervention group (1.8 mmHg(-1)×10(-3); 95% confidence interval, 0.1 to 3.6 mmHg(-1)×10(-3)). There were no intervention-related withdrawals or adverse events.

CONCLUSIONS

In patients new to HD, individualized cooled dialysate did not alter the primary outcome but was well tolerated and slowed the progression of HD-associated cardiomyopathy. Because cooler dialysate is universally applicable at no cost, the intervention warrants wider adoption or confirmation of these findings in a larger trial.

A simple and feasible method to determine absolute blood volume in hemodialysis patients in clinical practice

BACKGROUND

We developed a simple method to determine the absolute blood volume (V) during hemodialysis in everyday clinical practice and examined its relationship with volume overload, clinical relevance, and accuracy.

METHODS

The increase in relative blood volume (RBVpost - RBVpre) measured before and after infusion of 240 ml of ultra-pure dialysate using the bolus function of a commercial online hemodiafiltration machine incorporating a relative blood volume monitor was applied to determine absolute blood volume. The specific blood volume (Vs, blood volume per kg body mass at dry weight, in ml/kg) was compared to volume status as assessed by bioimpedance analysis and clinical criteria.

RESULTS

The blood volume measured in 30 stable hemodialysis patients was 6.51 ± 1.70 l at the beginning, corresponding to a specific blood volume of 80.1 ± 12.8 ml/kg, and dropped to 5.84 ± 1.61 l or 72.0 ± 12.1 ml/kg at the end of the dialysis session, respectively. Specific blood volume correlated with volume status assessed both clinically and by bioimpedance analysis. Intradialytic morbid events occurred only in treatments where specific blood volume fell below 65 ml/kg. The reproducibility of the technique was better than 4% and the in vitro accuracy corresponds to a resolution in Vs of better than 1 ml/kg.

CONCLUSION

Absolute blood volume can be easily measured at the beginning of the dialysis session using the current dialysis technology. Information about V and Vs could be a promising tool to avoid intradialytic morbid events. This technique could be completely automated without altering the hardware of currently available online dialysis devices. Therefore, it is recommended that this technique be integrated into all hemodiafiltration machines.

Difference between true functional haemoglobin and pre-dialysis haemoglobin is associated with plasma volume variation: a multicentre study

PURPOSE

Due to the well-known intradialytic haemoglobin (Hb) change, it has been suggested that true functional Hb differs from pre-dialysis Hb. However, mechanisms of this change are not understood properly. We aimed at studying the role of plasma volume variation.

METHODS

This is a multicentre study with two consecutive phases. First, true functional Hb was predicted by Krisper's formula that estimates time-averaged haemoglobin concentration (TAC-Hb) and by the average (Avg-Hb) of Pre-Hb and Post-Hb (n = 346). Erythropoiesis-stimulating agent (ESA) doses were estimated according to the FDA instructions. Second, we investigated the correlations between Hb changes (ΔHb), body weight loss (ΔBW) and relative plasma volume changes (%ΔPV) in subjects with a weight gain higher than 1 kg (n = 208).

RESULTS

First: Avg-Hb and TAC-Hb were similar to each other and higher than midweek Pre-Hb (p < 0. 002). Odds of having an Hb change >1 g/dL were 0.415. Odds were similar in both women and men [odds ratio (OR) 0.923; 95 % confidence interval (CI) 0.591-1.441]. If ESA doses were estimated by TAC-Hb or Avg-Hb instead of Pre-Hb, they should be lower in 40 % of the 346 patients. Second: Mean %ΔPV was -12.1 % (95 % CI -10.72/-13.48), and mean ΔHb was 1.1 g/dL (95 % CI 0.97/1.25). Correlation between ΔHb and %ΔPV was -0.92 (r (2) 0.84) whereas that of ΔHb/ΔBW was just -0.45 (r (2) 0.21; p < 0.000). Prevalence of ΔHb >1 g/dL was independent of ΔBW from 1.4 to 6.3 kg. By contrast, prevalence of ΔHb >1 g/dL in %ΔPV quartiles was clearly linear: 0, 52, 90 and 100 %, respectively.

CONCLUSIONS

Plasma volume variations play a major role in intradialytic Hb change. True functional Hb should be estimated in all patients with a weight gain higher than 1 kg.

Volume excess in chronic haemodialysis patients--effects of treatment frequency and treatment spacing

BACKGROUND

The main objective of this study was to theoretically quantify the fluctuations of fluid volume excess for different modes of intermittent ultrafiltration schedules and to compare the prediction for the typical and asymmetric thrice-weekly schedule to clinical, physiological and biophysical markers of volume expansion in a group of stable haemodialysis patients.

METHODS

Overall volume excess (V(OVE)) was described as the sum of a time-independent (V(0)) and a time-dependent component (V). An exact relationship was developed to relate V to variable treatment frequency, treatment spacing and net volume accumulation rate. In a single-centre haemodialysis population, body mass profiling was combined with volume state evaluation by bioimpedance analysis, N-terminal pro-B-type natriuretic peptide (NT-pro BNP) levels, clinical signs, a volume questionnaire and blood pressure levels.

RESULTS

In 23 patients following the typical thrice-weekly schedule, the time-averaged volume excess (V) during the whole week (1.1 ± 0.5 L) was significantly larger than that during the midweek interval (0.9 ± 0.4 L) (P < 0.002) by a factor comparable to that of 1.21 obtained from the theoretical analysis. V(OVE) was 1.3 ± 1.7 L and significantly related to pre- (P < 0.001) and post-dialysis levels of NT-pro BNP (P < 0.001).

CONCLUSION

Asymmetric treatment spacing such as with the typical thrice-weekly treatment schedule leads to a significant increase in time-averaged volume excess. The theoretical analysis allows for comparison of time-averaged volume excess in treatments varying with regard to treatment frequency and regularity and could be helpful to prescribe post-treatment volume (target weight) for such variable treatment modes.

Three months of regular gum chewing neither alleviates xerostomia nor reduces overhydration in chronic hemodialysis patients

INTRODUCTION AND AIMS

Gum chewing has been known to be a part of adjunctive medical therapy for cancer-related xerostomia. Nonadherence to fluid restriction in hemodialysis (HD) patients brought about by unrestricted thirst and xerostomia leads to excessive interdialytic weight gain (IWG). The effectiveness of gum chewing in reducing thirst in HD patients has till recently been evaluated by only a single study with short 2-week intervention period. The aim of the present study was to assess the effect of 3 months of regular use of sugar-free chewing gum on xerostomia, thirst, and hydration and nutritional status in HD patients.

METHODS

A prospective pre/post (3 + 1 month[s]) study including 38 chronic HD patients (14 women, 17 men; mean age, 59 ± 10 years; time on dialysis, 48 ± 45 months) with mean mid-week IWG of >1 kg, persistent xerostomia, and/or thirst was conducted. Seven patients did not complete the study including 3 because of suspected side effects of gum chewing (diarrhea or paradoxically increased thirst). After a 2-week run-in period, the subjects received a specified number of packs of low-tack, sugar-free chewing gum and specially designed diaries. Basic biochemistry and multifrequency electric bioimpedance were performed a total of 8 times, that is, at baseline and after each month of the intervention period, both before and after dialysis. Questionnaires related to xerostomia and thirst were filled in by the patients at baseline, at the end of the intervention period, and 1 month later. Body weight (for IWG assessment) and blood pressure were measured at the start of each dialysis for the whole duration of the study.

RESULTS

The mean number of chewing gum pellets used during the first and the third month of the study was 137 ± 56 and 139 ± 59, respectively. The patients did not report experiencing any changes in the intensity of xerostomia and thirst during the study. Total body water content assessed with bioimpedance did not decrease (41.9 ± 8.9 kg at baseline vs. 42.7 ± 9.1 kg at the end of the intervention period). Moreover, no changes in extracellular mass (31.9 ± 6.4 kg vs. 32.6 ± 6.6 kg), extracellular water (18.0 ± 5.2 kg vs. 18.3 ± 5.0 kg), and phase angle (4.6 ± 0.8 vs. 4.6 ± 0.8) were observed. Mean IWG between 2 mid-weekly HD sessions also did not change (2.3 ± 0.8 kg at baseline vs. 2.3 ± 0.9 kg at the end of the intervention period). No significant changes in thirst and xerostomia were observed 4 weeks after the end of the intervention period; however, mean IWG between 2 mid-weekly HD sessions increased to 2.8 ± 1.0 kg (P < .001).

CONCLUSIONS

Regular gum chewing is known to be well tolerated by most HD patients; however, it does not lead to the alleviation of xerostomia or excessive thirst and does not reduce IWG or improve hydration status.

Microcirculatory changes and skeletal muscle oxygenation measured at rest by non-infrared spectroscopy in patients with and without diabetes undergoing haemodialysis

Introduction

Haemodialysis has direct and indirect effects on skin and muscle microcirculatory regulation that are severe enough to worsen tolerance to physical exercise and muscle asthenia in patients undergoing dialysis, thus compromising patients' quality of life and increasing the risk of mortality. In diabetes these circumstances are further complicated, leading to an approximately sixfold increase in the incidence of critical limb ischaemia and amputation. Our aim in this study was to investigate in vivo whether haemodialysis induces major changes in skeletal muscle oxygenation and blood flow, microvascular compliance and tissue metabolic rate in patients with and without diabetes.

Methods

The study included 20 consecutive patients with and without diabetes undergoing haemodialysis at Sant Andrea University Hospital, Rome from March to April 2007. Near-infrared spectroscopy (NIRS) quantitative measurements of tissue haemoglobin concentrations in oxygenated [HbO₂] and deoxygenated forms [HHb] were obtained in the calf once hourly for 4 hours during dialysis. Consecutive venous occlusions allowed one to obtain muscular blood flow (mBF), microvascular compliance and muscle oxygen consumption (mVO₂). The tissue oxygen saturation (StO₂) and content (CtO₂) as well as the microvascular bed volume were derived from the haemoglobin concentration. Nonparametric tests were used to compare data within each group and among the groups and with a group of 22 matched healthy controls.

Results

The total haemoglobin concentration and [HHb] increased significantly during dialysis in patients without and with diabetes. Only in patients with diabetes, dialysis involved a [HbO₂], CtO₂ and increase but left mVO₂ unchanged. Multiple regression StO₂ analysis disclosed a significant direct correlation of StO₂ with HbO₂ and an inverse correlation with mVO₂. Dialysis increased mBF only in diabetic patients. Microvascular compliance decreased rapidly and significantly during the first hour of dialysis in both groups.

Conclusions

Our NIRS findings suggest that haemodialysis in subjects at rest brings about major changes in skeletal muscle oxygenation, blood flow, microvascular compliance and tissue metabolic rate. These changes differ in patients with and without diabetes. In all patients haemodialysis induces changes in tissue haemoglobin concentrations and microvascular compliance, whereas in patients with diabetes it alters tissue blood flow, tissue oxygenation (CtO₂, [HbO₂]) and the metabolic rate (mVO₂). In these patients the mVO₂ is correlated to the blood supply. The effects of haemodialysis on cell damage remain to be clarified. The absence of StO₂ changes is probably linked to an opposite [HbO₂] and mVO₂ pattern.

Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study

BACKGROUND

High ultrafiltration rate on haemodialysis (HD) stresses the cardiovascular system and could have a negative effect on survival.

METHODS

The effect of ultrafiltration rate (UFR; ml/h/kg BW) on mortality was prospectively evaluated in a cohort of 287 prevalent uraemic patients in regular HD from 1 January 2000 to 31 December 2005.

PATIENTS

165 men and 122 women, age 66 +/- 13 years, on regular HD for at least 6 months, median: 48 months (range 6-372 months). Mean UFR was 12.7 +/- 3.5 ml/h/kg BW, Kt/V: 1.27 +/- 0.13, body weight (BW): 62 +/- 13 kg, PCRn: 1.11 +/- 0.20 g/kg/day, duration of dialysis: median 240 min (range 180-300 min), mean arterial blood pressure (MAP) 99 +/- 9 mm/Hg. One hundred and forty nine patients (52%) died, mainly for cardiovascular reasons (69%). Multivariate Cox regression analysis was utilized to evaluate the effect on mortality of UFR, age, sex, dialytic vintage, cardiovascular disease (CVD), diabetes, dialysis modality, duration of HD, BW, interdialytic weight gain (IWG), body mass index (BMI), MAP, pulse pressure (PP), Kt/V, PCRn.

RESULTS

Age (HR 1.06; CI 1.04-1.08; P < 0.0001), PCRn (HR 0.17, CI 0.07-0.43; P < 0.0001), diabetes (HR 1.81, CI 1.24-2.47; P = 0.007), CVD (HR 1.86; CI 1.32-2.62; P = 0.007) and UFR (HR 1.22; CI 1.16-1.28; P < 0.0001) were identified as factors independently correlated to survival. We estimated the discrimination potential of UFR, evaluated at baseline, in predicting death at 5 years, calculating the relative receiver operating characteristic (ROC) curves and the cut-off that minimizes the absolute difference between sensitivity and specificity.

CONCLUSIONS

High UFRs are independently associated with increased mortality risk in HD patients. Better survival was observed with UFR < 12.37 ml/h/kg BW. For patients with higher UFRs, longer or more frequent dialysis sessions should be considered in order to prevent the deleterious consequences of excessive UFR.

Effect of High and Low Ultrafiltration Volume during Hemodialysis on Relative Blood Volume

Achieving an optimal post-hemodialysis hydration status may be difficult because objective criteria for dry weight are lacking. Both relative blood volume changes (DeltaRBV) at the end of hemodialysis and DeltaRBV normalized for ultrafiltration volume (DeltaRBV/UF ratio) have been reported to indicate post-hemodialysis volume status. A parameter for volume status should not be influenced by variations in ultrafiltration volume. However, if the volume that has to be ultrafiltrated to reach dry weight varies as a result of variations in pre-hemodialysis weight, either DeltaRBV or the DeltaRBV/UF ratio (or both) must change. To elucidate the relation between intradialytic ultrafiltration volume versus DeltaRBV and its derivative, the DeltaRBV/UF ratio, we studied the effect of a relatively high (mean+/- SD, 2.7+/- 0.5 l) and low (1.5+/- 0.3 l) intradialytic ultrafiltration volume on these parameters in eight patients. Post-hemodialysis weight was comparable in low and high ultrafiltration volume sessions. The average end-hemodialysis DeltaRBV did not differ between high (-6.7+/- 2.5%) and low ultrafiltration volume sessions (-7.3+/- 1.0%; NS), but the intraindividual variation was considerable. The DeltaRBV/UF ratio differed markedly (p<0.001) between high (-2.4+/- 0.8 %/l) and low (-4.9+/- 1.3 %/l) ultrafiltration volume sessions. In conclusion, the considerable random intraindividual variation of DeltaRBV and the systematic change of the DeltaRBV/UF ratio with variations in intradialytic ultrafiltration volume limit the use of these parameters as an aid to assess hydration status in hemodialysis patients.